Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Other Operating Expenses (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Other Operating Expenses for 3 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 22.43% to $28.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, down 22.43% year-over-year, with the annual reading at $28.7 million for FY2025, 22.43% down from the prior year.
  • Other Operating Expenses for Q4 2025 was $28.7 million at Rein Therapeutics, down from $37.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $37.0 million in Q4 2024, with the low at $28.7 million in Q4 2025.